1. Health Insurance Summit
Effects of Means Testing and Government Rebate
Andrew Goodsall
Analyst
andrew.goodsall@ubs.com +61 2 9324 3574
UBS Healthcare
Dan Hurren
Analyst
dan.hurren@ubs.com +61 2 9324 3575
This document has been prepared by UBS Securities Australia Ltd
UBS does and seeks to do business with companies covered in its research reports. As a result, investors should
be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors
should consider this report as only a single factor in making their investment decision.
July 2013
ANALYST CERTIFICATION AND REQUIRED DISCLOSURES BEGIN ON SLIDE 18
www.ubs.com/investmentreearch
2. 1
Agenda
Means test & rebate cap – background
Existing trends and projections on impact
Impact for health fund underwriting margins
Longer term consequences…
Has the industry peaked?
3. 2
Means test & rebate cap – background
Rudd letter…
How much time does
that letter ‘buy’ the
industry?
Source: Released by AHIA
4. 3
Means test & rebate cap – here to stay
How long?….about 6mths
Reforms announced May 08
All Labor Prime Ministers support the changes
Opposition unlikely to reverse in the near term
Source: Parliament of Australia; Official Stock Photo
5. 4
Means test & rebate cap – Reforms
4 major policy ‘hit’s within 5 years:
–2008 - Medicare Levy (MLS) threshold for PHI
lifted
–2009 - means testing for the 30% rebate
applied; eventually introduced in 2012
–2013 - Capping PHI rebate to fixed sum + CPI
rather than 30%
–2013 - Withdraw rebate on any lifetime penalty
component
Government appear determined to test the
resilience of the PHI industry
6. 5
Means test & rebate cap – background
Government policy is crucial
20%
25%
30%
35%
40%
45%
50%
FY96 FY97 FY98 FY99 FY00 FY01 FY02 FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12
Lifetime Health
Cover introduced
Intro of Medicare
Levy Surcharge
Higher rebates for
older persons
introduced April 05
Medicare Levy
Surcharge altered
30% rebate
introduced
Means testing of PHI
rebate
PHI rebate capped
Source: PHIAC, UBS
7. 6
Impact…crying wolf?
Initial drop out estimates did not materialise from
MLS change
Tax ‘trap’ penalty is deterrent to drop altogether…
8. 7
Impact…slow burn
More likely outcome:
–Lower cost policies
–Policies with exclusions
–Higher Excess policies
–Demographic mix shift
10. 99
Existing trends and projections on impact
Source: PHIAC, UBS
0%
1%
2%
3%
4%
5%
6%
7%
8%
Jun-06
Dec-06
Jun-07
Dec-07
Jun-08
Dec-08
Jun-09
Dec-09
Jun-10
Dec-10
Jun-11
Dec-11
Jun-12
Dec-12
Growth in new members <65 years old Growth in new members >65
0
40
80
120
160
0–4
5–9
10–14
15–19
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
95+
('000)
Net new PHI member by age cohort Mar 09 to Mar 13
Growth in new members by age cohort over time
Older cohort fastest growth
Continued skew to high
utilisation growth; >65 year old
cohort, growing +5.9%; or >2X
the rate of under 65's
Older cohort most expensive
cohort
12. 1111
Projecting trend line forward
Source: UBSe
Projected Growth in Private Health Fund Membership
80
100
120
140
160
180
200
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Total Fund Growth Growth (Under 60) Growth (Over 60)
13. 12
Existing trends – impact on industry
health
Underwriting performance:
Profit margin fell 180bps to 7.6% in FY12
Industry net margin currently at 4.8%, down 44 bps
on pcp.
14. 13
And now for moment of truth on rebate…
Source: Galaxy Poll, Company estimates, UBS Modelling, PHIAC Data
>1m policies impacted (~20% of policies)
–c.2.3m individuals to be affected
~20% of those affected, prepaid
– avoided impact for 12 months
–Prepayments increased by $1.2b in Jun12 qtr
>70% have relied upon apathy and ignored
53% of those affected are yet to make any
changes to cover
15. 14
Existing trends and projections on impact
Estimates : Impact will range from $339 to
$1000 per person
Modelling Suggests:
–For each 1% of those affected to downgrade
= 0.15% hit to industry net margin
–If 33% of those affected downgrade,
……industry net margin = 0
Source: Galaxy Poll, Company estimates, UBS Modelling, PHIAC Data
16. 1515
Longer term consequences…
Initial impact was modest with slower membership growth
(down from ~4% to ~1%) but soon rebounded to ~2.5%
growth pa
Growth appears steady at ~2.5% pa but:
– Membership numbers may not tell the whole story…..
– Impact deferred by pre paying until end FY13
– PHI reform – a focus for Australians completing their
tax returns in 2013? …and a 'retrospective' $1000
liability?
17. 16
Longer term consequences…
If there is a impact to underwriting margins
Response will include increase to premiums
Current trend is >5% pa
Unsustainable in itself into the longer term,
particularly for those on fixed incomes with just CPI
adjustments
Affordability death spiral…
We have been here before…
18. 17
Addendum: Industry = $15.5b
Industry Snapshot
Premium revenue: $15,422
Investment revenue: $557
Net HRB and other revenue: $50
Benefits: $13,162
Total expenses: $1,411
Profit before tax: $1,457
Source: PHIAC
19. 18
Analyst certification & required disclosures
Analyst Certification
Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst
covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent
manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views
expressed by that research analyst in the research report.
20. 19
Required disclosures
UBS Securities Australia Limited: Andrew Goodsall
Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.
KEY DEFINITIONS
Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months.
Market Return Assumption (MRA) is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium).
Under Review (UR) Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in
response to an event that may affect the investment case or valuation.
Short-Term Ratings reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case.
Equity Price Targets have an investment horizon of 12 months.
EXCEPTIONS AND SPECIAL CASES
UK and European Investment Fund ratings and definitions are: Buy: Positive on factors such as structure, management, performance record, discount; Neutral: Neutral on factors
such as structure, management, performance record, discount; Sell: Negative on factors such as structure, management, performance record, discount.
Core Banding Exceptions (CBE): Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the
stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate
to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.
Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with the NASD and
NYSE and therefore are not subject to the restrictions contained in the NASD and NYSE rules on communications with a subject company, public appearances, and trading securities
held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.
21. 20
Contact information
UBS Securities Australia Ltd
Andrew Goodsall
Healthcare Analyst
andrew.goodsall@ubs.com
Tel:
+61 2 9324 3674
Fax: +61 2 9324 3675
Level 16
Chifley Tower
2 Chifley Square
Sydney NSW 2000
Australia
www.ubs.com
22. 21
Global disclaimer
This document has been prepared by UBS Securities Australia Ltd, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.
This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction
where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes; it is
not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either express or implied, is provided in relation to the
accuracy, completeness or reliability of the information contained in this document (‘the Information’), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the
securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to
opinions expressed by other business areas or groups of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either
publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party.
Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor’s individual circumstances or otherwise constitutes a personal recommendation.
Investments involve risks, and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to
certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and
may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the
document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.
The value of any investment or income may go down as well as up, and investors may not get back the full amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors,
employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.
Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected
at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield
substantially different results.
Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained in this document is based on numerous assumptions. Different assumptions could
result in materially different results. The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting
market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this
document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the
revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.
For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these
terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such
information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with
the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred
to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the
opinions expressed in this document.
